Shira Perl

4.2k total citations · 1 hit paper
37 papers, 2.4k citations indexed

About

Shira Perl is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Shira Perl has authored 37 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Surgery and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Shira Perl's work include Diabetes Management and Research (6 papers), Gout, Hyperuricemia, Uric Acid (6 papers) and Pancreatic function and diabetes (5 papers). Shira Perl is often cited by papers focused on Diabetes Management and Research (6 papers), Gout, Hyperuricemia, Uric Acid (6 papers) and Pancreatic function and diabetes (5 papers). Shira Perl collaborates with scholars based in United States, Sweden and France. Shira Perl's co-authors include John F. Tisdale, Jonas Frisén, Mehran Salehpour, Samuel Bernard, Kanar Alkass, Göran Possnert, Henrik Druid, Aurélie Ernst, Pedro Réu and Jeff E. Mold and has published in prestigious journals such as New England Journal of Medicine, Cell and Journal of Biological Chemistry.

In The Last Decade

Shira Perl

37 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neurogenesis in the Striatum of the Adult Human Brain

2014 705 citations Shira Perl, John F. Tisdale et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shira Perl United States	15	721	717	580	521	404	37	2.4k
I. K. Hart United Kingdom	21	797 1.1×	1.2k 1.6×	337 0.6×	258 0.5×	193 0.5×	38	3.5k
Lawrence M. Shuer United States	20	359 0.5×	1.4k 2.0×	911 1.6×	232 0.4×	255 0.6×	45	3.5k
Betty Soliven United States	35	483 0.7×	1.6k 2.2×	585 1.0×	247 0.5×	141 0.3×	86	3.9k
Adam M. H. Young United Kingdom	22	355 0.5×	912 1.3×	1.4k 2.4×	184 0.4×	221 0.5×	62	3.4k
Urmas Arumäe Finland	29	966 1.3×	1.8k 2.5×	292 0.5×	456 0.9×	312 0.8×	57	3.9k
Peter Bannerman United States	33	719 1.0×	1.3k 1.8×	530 0.9×	177 0.3×	128 0.3×	67	2.8k
Ralf Stumm Germany	38	718 1.0×	1.5k 2.0×	831 1.4×	193 0.4×	112 0.3×	66	4.1k
Jianwei Jiao China	34	676 0.9×	1.8k 2.4×	323 0.6×	122 0.2×	376 0.9×	124	3.2k
Roberto Gradini Italy	31	258 0.4×	1.2k 1.7×	168 0.3×	181 0.3×	227 0.6×	71	2.7k
Roland Pochet Belgium	42	318 0.4×	2.6k 3.6×	523 0.9×	331 0.6×	189 0.5×	126	4.6k

Countries citing papers authored by Shira Perl

Since Specialization

Citations

This map shows the geographic impact of Shira Perl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shira Perl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shira Perl more than expected).

Fields of papers citing papers by Shira Perl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shira Perl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shira Perl. The network helps show where Shira Perl may publish in the future.

Co-authorship network of co-authors of Shira Perl

This figure shows the co-authorship network connecting the top 25 collaborators of Shira Perl. A scholar is included among the top collaborators of Shira Perl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shira Perl. Shira Perl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flack, John M., Michel Azizi, Jenifer M. Brown, et al.. (2025). Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine. 393(14). 1363–1374. 11 indexed citations

Flack, John M., Michel Azizi, Jenifer M. Brown, et al.. (2025). Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertension Research. 48(11). 2911–2923. 3 indexed citations

Heerspink, Hiddo J.L., Austin G. Stack, Robert Terkeltaub, et al.. (2024). Combination Treatment with Verinurad and Allopurinol in CKD. Journal of the American Society of Nephrology. 35(5). 594–606. 15 indexed citations

Kitzman, Dalane W., Adriaan A. Voors, Robert J. Mentz, et al.. (2024). Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction. JAMA Cardiology. 9(10). 892–892. 4 indexed citations

Kiddle, Steven J., Karolina Andersson Sundell, Shira Perl, Stephen Nolan, & Magnus Bjursell. (2024). Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink. Clinical Cardiology. 47(6). e24297–e24297. 3 indexed citations

Kitzman, Dalane W., Adriaan A. Voors, Robert J. Mentz, et al.. (2021). RATIONALE AND DESIGN FOR A PHASE 2 TRIAL OF VERINURAD PLUS ALLOPURINOL IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND HYPERURICEMIA. Journal of the American College of Cardiology. 77(18). 597–597. 2 indexed citations

Carnicelli, Anthony, Robert M. Clare, Karen Chiswell, et al.. (2020). Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. The American Journal of Cardiology. 127. 64–72. 11 indexed citations

Carnicelli, Anthony, Jie‐Lena Sun, Brooke Alhanti, et al.. (2020). Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. The American Journal of Medicine. 133(12). e716–e721. 14 indexed citations

Karmaus, Peer W. F., Min Shi, Shira Perl, et al.. (2019). Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight. 4(21). 18 indexed citations

10.

Khurana, Surender, Elizabeth M. Coyle, Jody Manischewitz, et al.. (2018). AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. npj Vaccines. 3(1). 46 indexed citations

11.

El‐Chemaly, Souheil, Foo Cheung, Yuri Kotliarov, et al.. (2018). The Immunome in Two Inherited Forms of Pulmonary Fibrosis. Frontiers in Immunology. 9. 76–76. 19 indexed citations

12.

Perl, Shira, W. James Cook, Cheryl Wei, Peter Öhman, & Boaz Hirshberg. (2016). Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Clinical Therapeutics. 38(12). 2578–2588. 5 indexed citations

13.

Olnes, Matthew J., Yuri Kotliarov, Angélique Biancotto, et al.. (2016). Effects of Systemically Administered Hydrocortisone on the Human Immunome. Scientific Reports. 6(1). 23002–23002. 122 indexed citations

14.

Gordon, Scott M., et al.. (2015). Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties*. Molecular & Cellular Proteomics. 14(12). 3247–3257. 48 indexed citations

15.

Biancotto, Angélique, Shira Perl, Matthew J. Olnes, et al.. (2013). Baseline Levels and Temporal Stability of 27 Multiplexed Serum Cytokine Concentrations in Healthy Subjects. PLoS ONE. 8(12). e76091–e76091. 84 indexed citations

16.

Perl, Shira, et al.. (2013). Addition of Rapamycin to Anti-CD3 Antibody Improves Long-Term Glycaemia Control in Diabetic NOD Mice. PLoS ONE. 8(6). e67189–e67189. 7 indexed citations

17.

Quintana, Francisco J., Shira Perl, Irit Meivar‐Levy, et al.. (2007). Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. Journal of Autoimmunity. 28(2-3). 134–142. 55 indexed citations

18.

Ueda, Takahiro, Sebastian Brenner, Harry L. Malech, et al.. (2004). Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene. Journal of Biological Chemistry. 280(2). 991–998. 15 indexed citations

19.

Perl, Shira, et al.. (2003). Functional, Persistent, and Extended Liver to Pancreas Transdifferentiation. Journal of Biological Chemistry. 278(34). 31950–31957. 208 indexed citations

20.

Perl, Shira, et al.. (1992). Ventricular performance in relation to heart rate and AV delay at rest. European Heart Journal. 13(suppl E). 91–98. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact